Insilico (ASX: 03696) has announced a strategic alliance with Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing. This multi-faceted alliance is designed to establish a broad framework for extensive collaboration, with specific details to be finalized through further discussions and a definitive agreement. If fully implemented, the potential value of the proposed collaboration is expected to exceed $2.5 billion.

The collaboration, to be governed by subsequent negotiations and a final agreement, aims to combine Insilico's technological strengths in target discovery, generative chemistry, and molecular optimization through its proprietary Pharma.AI platform with Bora Pharmaceuticals' expertise in global drug development, manufacturing, quality management, and commercialization. By integrating AI-enabled research systems with automated development, manufacturing, and quality execution processes, the two companies seek to pioneer a new generation of drug innovation. Their goal is to bridge the capabilities required to design, develop, manufacture, and deliver novel molecules to patients with unmet medical needs.